Treatment of bacillus calmette-guérin refractory non-muscle invasive bladder cancer

Basit Öğe Kaydı
dc.contributor.authorTurker, Polat
dc.contributor.authorTurkeri, Levent
dc.date.accessioned2024-10-29T17:43:53Z
dc.date.available2024-10-29T17:43:53Z
dc.date.issued2013
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractTreatment options for patients with non-muscle invasive bladder cancer (NMIBC) refractory to intravesical bacillus Calmette-Guérin (BCG) therapy is reviewed in this article based on the recent published literature. Although intravesical BCG is the best bladder sparing treatment option for NMIBC to prevent recurrence and progression, about 1/3 of cases are refractory to this treatment. At this point radical cystectomy is the standard treatment of choice. If this option is not feasible, intravesical chemotherapy with docetaxel or gemcitabine, the combination of BCG and interferon (INF)-á or device-assisted intravesical strategies, such as mitomycin-EMDA or chemohyperthermia are some of the candidates for further treatment.
dc.identifier.endpage840
dc.identifier.issn0004-0614
dc.identifier.issue9en_US
dc.identifier.pmid24231293
dc.identifier.scopus2-s2.0-84887503110
dc.identifier.scopusqualityQ4
dc.identifier.startpage833
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12669
dc.identifier.volume66
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.relation.ispartofArchivos Espanoles de Urologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBCG failure
dc.subjectItravesical therapy
dc.subjectNon-muscle invasive bladder cancer
dc.titleTreatment of bacillus calmette-guérin refractory non-muscle invasive bladder cancer
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu